Revealing the Interaction Mechanism between Mycobacterium tuberculosis GyrB and Novobiocin, SPR719 through Binding Thermodynamics and Dissociation Kinetics Analysis

• Published in: International journal of molecular sciences 2024-04, Vol.25 (7), p.3764
• Main Authors: Qiu, Xiaofei, Zhang, Qianqian, Li, Zhaoguo, Zhang, Juan, Liu, Huanxiang
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adenosine Triphosphate; AIDS; Antitubercular Agents - pharmacology; binding mechanism; Binding sites; Clinical trials; Decomposition; Drug resistance; Energy; Flexibility; GyrB; Infectious diseases; Ligands; molecular dynamics (MD) simulations; Molecular Dynamics Simulation; Mycobacterium tuberculosis; novobiocin; Novobiocin - pharmacology; Proteins; Simulation; SPR719; Staphylococcus infections; Thermodynamics; Tropical diseases; Tuberculosis
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25073764

With the rapid emergence of drug-resistant strains of (Mtb), various levels of resistance against existing anti-tuberculosis (TB) drugs have developed. Consequently, the identification of new anti-TB targets and drugs is critically urgent. DNA gyrase subunit B (GyrB) has been identified as a potential anti-TB target, with novobiocin and SPR719 proposed as inhibitors targeting GyrB. Therefore, elucidating the molecular interactions between GyrB and its inhibitors is crucial for the discovery and design of efficient GyrB inhibitors for combating multidrug-resistant TB. In this study, we revealed the detailed binding mechanisms and dissociation processes of the representative inhibitors, novobiocin and SPR719, with GyrB using classical molecular dynamics (MD) simulations, tau-random acceleration molecular dynamics (τ-RAMD) simulations, and steered molecular dynamics (SMD) simulations. Our simulation results demonstrate that both electrostatic and van der Waals interactions contribute favorably to the inhibitors' binding to GyrB, with Asn52, Asp79, Arg82, Lys108, Tyr114, and Arg141 being key residues for the inhibitors' attachment to GyrB. The τ-RAMD simulations indicate that the inhibitors primarily dissociate from the ATP channel. The SMD simulation results reveal that both inhibitors follow a similar dissociation mechanism, requiring the overcoming of hydrophobic interactions and hydrogen bonding interactions formed with the ATP active site. The binding and dissociation mechanisms of GyrB with inhibitors novobiocin and SPR719 obtained in our work will provide new insights for the development of promising GyrB inhibitors.